Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MGTX |
---|---|---|
09:32 ET | 400 | 4.03 |
09:36 ET | 874 | 4.03 |
09:38 ET | 5048 | 3.94 |
09:39 ET | 400 | 3.93 |
09:41 ET | 200 | 3.93 |
09:43 ET | 200 | 3.94 |
09:45 ET | 200 | 3.94 |
09:48 ET | 100 | 3.94 |
09:50 ET | 200 | 3.975 |
09:52 ET | 700 | 3.93 |
09:54 ET | 100 | 3.93 |
09:56 ET | 100 | 3.93 |
09:57 ET | 1300 | 3.96 |
09:59 ET | 699 | 3.98 |
10:03 ET | 150 | 3.97 |
10:10 ET | 300 | 3.99 |
10:15 ET | 100 | 3.96 |
10:17 ET | 585 | 3.95 |
10:19 ET | 340 | 3.96 |
10:21 ET | 738 | 3.95 |
10:24 ET | 261 | 3.93 |
10:26 ET | 500 | 3.9699 |
10:28 ET | 821 | 3.92 |
10:30 ET | 400 | 3.92 |
10:32 ET | 339 | 3.94 |
10:33 ET | 100 | 3.91 |
10:35 ET | 100 | 3.91 |
10:37 ET | 300 | 3.91 |
10:39 ET | 200 | 3.91 |
10:44 ET | 2295 | 3.93 |
10:46 ET | 380 | 3.93 |
10:48 ET | 629 | 3.92 |
10:50 ET | 789 | 3.92 |
10:53 ET | 487 | 3.92 |
10:57 ET | 3180 | 3.96 |
11:00 ET | 300 | 3.94 |
11:02 ET | 600 | 3.93 |
11:04 ET | 450 | 3.92 |
11:06 ET | 300 | 3.92 |
11:08 ET | 486 | 3.91 |
11:09 ET | 500 | 3.92 |
11:11 ET | 100 | 3.91 |
11:18 ET | 660 | 3.925 |
11:20 ET | 3081 | 3.935 |
11:22 ET | 600 | 3.97 |
11:36 ET | 1388 | 3.96 |
11:42 ET | 200 | 3.98 |
11:54 ET | 100 | 3.97 |
11:56 ET | 900 | 3.99 |
12:12 ET | 100 | 3.97 |
12:16 ET | 100 | 3.97 |
12:23 ET | 300 | 3.98 |
12:25 ET | 600 | 3.98 |
12:30 ET | 100 | 3.98 |
12:32 ET | 200 | 3.97 |
12:34 ET | 331 | 3.96 |
12:38 ET | 383 | 3.96 |
12:39 ET | 300 | 3.93 |
12:41 ET | 200 | 3.93 |
12:43 ET | 400 | 3.93 |
12:45 ET | 300 | 3.925 |
12:48 ET | 961 | 3.94 |
12:50 ET | 200 | 3.93 |
12:52 ET | 300 | 3.93 |
12:54 ET | 200 | 3.93 |
12:56 ET | 100 | 3.93 |
12:57 ET | 300 | 3.93 |
12:59 ET | 100 | 3.935 |
01:01 ET | 1000 | 3.95 |
01:15 ET | 100 | 3.96 |
01:21 ET | 100 | 3.95 |
01:26 ET | 100 | 3.95 |
01:28 ET | 100 | 3.95 |
01:30 ET | 100 | 3.95 |
01:33 ET | 100 | 3.95 |
01:35 ET | 100 | 3.95 |
01:39 ET | 100 | 3.95 |
01:42 ET | 100 | 3.95 |
01:44 ET | 100 | 3.95 |
01:48 ET | 100 | 3.95 |
01:50 ET | 100 | 3.95 |
01:53 ET | 100 | 3.95 |
01:55 ET | 100 | 3.95 |
01:57 ET | 1410 | 3.98 |
02:18 ET | 100 | 3.98 |
02:20 ET | 100 | 3.99 |
02:22 ET | 100 | 3.99 |
02:24 ET | 100 | 3.99 |
02:26 ET | 100 | 3.98 |
02:27 ET | 400 | 3.98 |
02:29 ET | 100 | 3.98 |
02:36 ET | 1076 | 3.99 |
02:42 ET | 1200 | 4 |
02:44 ET | 100 | 3.99 |
02:49 ET | 100 | 3.98 |
02:51 ET | 100 | 3.98 |
02:54 ET | 100 | 3.98 |
02:56 ET | 100 | 3.98 |
02:58 ET | 200 | 3.98 |
03:02 ET | 633 | 3.99 |
03:09 ET | 1150 | 4 |
03:18 ET | 1200 | 4.025 |
03:21 ET | 100 | 4.0109 |
03:23 ET | 200 | 4.01 |
03:30 ET | 331 | 4.01 |
03:32 ET | 637 | 4 |
03:34 ET | 100 | 4 |
03:38 ET | 100 | 4 |
03:39 ET | 100 | 4.01 |
03:41 ET | 100 | 4.01 |
03:43 ET | 100 | 4 |
03:45 ET | 600 | 4.01 |
03:48 ET | 1581 | 4.02 |
03:50 ET | 100 | 4.02 |
03:52 ET | 900 | 4.03 |
03:54 ET | 1461 | 4.05 |
03:56 ET | 2391 | 4.05 |
03:57 ET | 394 | 4.05 |
03:59 ET | 1944 | 4.02 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
MeiraGTx Holdings PLC | 258.5M | -3.2x | --- |
Molecular Partners AG | 236.8M | -3.3x | --- |
Uniqure NV | 189.8M | -0.6x | --- |
TScan Therapeutics Inc | 309.8M | -4.5x | --- |
C4 Therapeutics Inc | 313.1M | -1.9x | --- |
Black Diamond Therapeutics Inc | 249.8M | -2.6x | --- |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $258.5M |
---|---|
Revenue (TTM) | $11.4M |
Shares Outstanding | 64.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.34 |
EPS | $-1.27 |
Book Value | $2.17 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 22.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.